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Abstract
Antiestrogens are designed to antagonize hormone induced proliferation and ERa target gene expression in mammary
tumor cells. Commonly used drugs such as OH-Tamoxifen and ICI 182780 (Fulvestrant) block cell cycle progression in G0/G1.
Inversely, the effect of cell cycle stage on ER regulated gene expression has not been tested directly. We show that in ERa-
positive breast cancer cells (MCF-7) the estrogen receptor gene and downstream target genes are cell cycle regulated with
expression levels varying as much as three-fold between phases of the cell cycle. Steroid free culture conditions commonly
used to assess the effect of hormones or antiestrogens on gene expression also block MCF-7 cells in G1-phase when several
ERa target genes are overexpressed. Thus, cell cycle effects have to be taken into account when analyzing the impact of
hormonal treatments on gene transcription. We found that antiestrogens repress transcription of several ERa target genes
specifically in S phase. This observation corroborates the more rapid and strong impact of antiestrogen treatments on cell
proliferation in thymidine, hydroxyurea or aphidicolin arrested cells and correlates with an increase of apoptosis compared
to similar treatments in lovastatin or nocodazol treated cells. Hence, cell cycle effects synergize with the action of
antiestrogens. An interesting therapeutic perspective could be to enhance the action of anti-estrogens by associating
hormone-therapy with specific cell cycle drugs.
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Introduction
Estrogens play a key role in the development of the mammary
gland. In the normal gland, proliferating cells do not express
estrogen receptors. In contrast, estrogen receptor-a (ERa) which
acts as a ligand (estrogen)-dependent transcription factor is
expressed in the majority of mammary tumors (70%). Recent
transcriptome analyses confirmed observations made over a
century ago, that estrogens stimulate the development of the
disease in at least one out of five patients [1,2,3].
The control of cell proliferation by estrogens such as 17-ß
estradiol (E2) is a complex process. Estrogens bound to ERa
regulate target genes implicated in proliferation including CDK2,
CDK4, Cyclin D1 (CCND1) or the proto-oncogene c-Myc (MYC)
[4,5,6]. In addition, several genes which negatively control cell
proliferation such as cyclin G2 (CCG2), caspase 9 (CSP9)o rp21 are
repressed by estrogens [7,8]. Rapidly and transiently, estrogens
activate signal transduction pathways, acting in particular through
mitogen-activated protein kinases (MAPK) [9,10]. The fact that
estrogens promote tumorigenesis has led to the development of
anti-hormone therapies. Synthetic compounds that either act as
estrogen-antagonists or block the function of aromatases (the
enzymes that catalyze the last step of estrogen biosynthesis) have
been designed. Several publications also reported an effect of anti-
estrogens on expression and/or intracellular distribution of factors
that regulate cell cycle progression. Anti-estrogens such as
Tamoxifen (OH-TAM) or ICI 182.780 (ICI) block ERa-positive
breast cancer cells in G1 [11,12].
The effects of estradiol and hormone-therapy on cell cyle
progression are very well documented [12,13,14,15] showing that
variations in ERa target gene expression largely influence cell
cycle regulators, including cyclins. In contrast little is published on
the variation of ESR1 and ERa target gene expression during the
course of the cell cycle. Previously, only expression of the
progesterone receptor gene (PGR) was studied during the cell
cycle in T47D cells [16].
In this study, we analysed commonly studied ERa target genes
involved in cell differentiation, such as TFF1 (pS2), estrogen
receptor (ESR1)o rPGR, and in cell proliferation, such as
Cathepsine-D (CTSD) and CCND1. We also included the gene
coding for the histone variant H2A.Z in our analysis. This gene is
indirectly regulated by ERa via c-myc, which leads to an increase in
transcription and H2A.Z protein synthesis in MCF-7 breast cancer
cell lines [6,17]. We have investigated whether the effect of several
commonly used antiestrogens such as OH-TAM and ICI on ERa
target gene expression and cell proliferation was dependent on the
cell cycle stage. We demonstrate that transcription of all ERa
target genes analysed is cell cycle regulated and that antiestrogens
and culture conditions affect cell cycle progression. We further
show that cell cycle effects influence the action of antiestrogens. In
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11011particular, we found that the effect of OH-TAM and ICI was
significantly enhanced in cells blocked in S phase by reduction of
gene expression and an increase in apoptosis.
Results
Estrogen-regulated gene expression is cell cycle
regulated
Under standard growth conditions, 58% of non confluent
MCF-7 cells are in G1, 25% in S and 17% in G2 phase (Figure 1A,
column 1) in the absence of cell cycle modifying drugs. MCF-7
cells were exposed to 20 mM lovastatin for 32 hours, 3 mM
thymidine or 50 ng/ml nocodazol for 24 hours. FACS analysis
confirmed that lovastatin (column 2) synchronized cells in G1
(82%), that a thymidine treatment (column 3) induced an S-phase
block (61%) and that nocodazol (column 4) lead to an arrest in
G2/M (72%) compared to asynchronous cells (column 1). We
chose lovastatin and thymidine over other cytotoxic compounds
for their limited toxicity. Indeed, minimal perturbations of general
metabolic functions occurred since the rate of RNA, protein, and
initial DNA synthesis were unaffected by Lovastatin [18]. In
particular, the use of 10 nM ICI, frequently found in the literature
to synchronize cells in G1 could not be employed for our study
since ICI is not neutral when examining ERa regulated gene
expression. We thus chose to synchronize cells in S-phase using
thymidine since this method is one of the most effective and most
widely used techniques. The rationale of this method based on
high concentrations of thymidine inhibiting ribonucleotide
reductase activity, and thereby DNA synthesis in S-phase cells
by depleting the nucleotide precursor pools of dCTP. No toxicity
with this compound naturally present in the cell is observed
contrary to hydroxyurea, 5 fluorouracil or aphidicolin which cause
DNA damage.
Using quantitative RT- PCR we analyzed ESR1, PGR, CCND1
and H2AFZ expression in synchronized cells. We found that
relative mRNA levels of ESR1 and PGR were about 2 fold higher
in G1 than in S-phase (Figure 1B) and 2 to 3 fold higher in G1
than in G2/M phase. Control RPLO and GAPDH gene
expression did not vary compared to G1 arrested cells. We note
that variations in expression levels of PGR were similar to the ones
reported by Nayaran et al. [16] in which serum starvation of T47D
cells was employed. CCND1 was also preferentially expressed in
G1, although significant amounts of mRNA were detected in S
and G2/M phases. Furthermore, H2AFZ expression in G1
corresponded to only ,50% of H2AFZ mRNA levels measured
in G2/M. We next analyzed gene expression in MCF-7 cells that
had been synchronized by nocodazol before check-off and further
growth (7 hours) to reach G1 (FACS, data not shown). Gene
expression levels were identical to the ones recorded in the
lovastatin G1 arrested sample (Figure 1C). We conclude that, in
MCF-7 cells, transcription of the estrogen receptor gene and of
ERa regulated target genes is cell cycle regulated.
In steroid free medium ERa positive MCF-7 cells arrest in
G1
Tumor derived MCF-7 cells are used to mimic hormone
sensitive breast cancers. Two types of media are commonly used:
red medium which is the standard medium for optimum growth
(DMEM F12 and derivatives), and white medium which is used to
analyze the expression of ERa target genes after addition of 17-ß
estradiol (E2). White medium is phenol red depleted since phenol
red is known to activate ERa gene regulation, and supplemented
with steroid free (charcoal treated) serum. MCF-7 cells were
cultivated in red and white medium with or without E2 reaching
near 60 to 70% confluence (Figure 2A). Cell cycle profiles in red
medium were almost identical with or without addition of E2
(10 nM). In contrast, after 3 days in white medium, a significant
fraction of MCF-7 cells accumulated in G1 phase (80% of the cells,
Figure 2A). A doubling time experiment (Figure 2A right panel)
confirmed that these cells stopped growing. Thus MCF-7 cells
cultivated in white medium are blocked in G1. This G1 block was
reversed 24 h after addition of E2 (10 nM). Between 1 h and 24 h
of E2 treatment we saw intermediate cell cycle profiles (data not
shown). We next analyzed gene expression under different culture
conditions (Figure 2B). E2 treatment in red medium reduced ESR1
expression. ESR1 is known to be down-regulated when ERa
protein levels increase. This negative feedback loop lead to a rapid
increase in ESR1 transcription (15 min) and a subsequent decrease
in mRNA levels as shown here 24 h after addition of E2. In white
medium, cells were blocked in G1 and we observed an increase in
ESR1 expression compared to red medium culture conditions in
agreement with our observation that ESR1 expression was greatest
in G1 (Figure 1B). Addition of E2 to either medium triggered a
50% reduction in ESR1 mRNA levels. PGR and CCND1 were
activated by addition of E2 independently of the type of medium.
After 24 h of E2 induction the expression levels of each gene tested
were similar in red and in white media. Therefore, white medium
culture conditions do not trigger any irreversible effect on cell
cycle and gene expression. However, when analyzing the effects of
drugs on gene expression, under steroid free culture conditions,
cell cycle effects have to be taken into account.
Regulation of gene expression by OH-Tam and ICI is cell
cycle dependent
The principal strategy for inhibition of estrogen-dependent
tumor growth is to block ERa signaling by anti-estrogen molecules
(competitive hormone-therapy) such as Tamoxifen (OH-TAM) or
Faslodex/ICI 182.780 (ICI). Numerous studies describe their
molecular mechanisms of action in MCF-7 cell cultures. While it is
clear that both classes of antiestrogens induce cells to arrest in G1,
it has not been investigated whether their effects were cell cycle
dependent [11,19,20,21].
In agreement with previous reports [11,20], OH-TAM and ICI
182.780 induced a strong G1 block in MCF-7 cells, and reduced
expression levels of estrogen-regulated genes (Figure 3). By
quantitative RT-PCR we observed a slight decrease of ESR1 gene
expression, whereas PGR expression was abolished and CCND1
expression was reduced by 25% to 35%. Similarly, H2AFZ
expression diminished by 30% and 40% after OH-TAM or ICI
treatments, respectively.
Next, we investigated the impact of antiestrogens on gene
expression in MCF-7 cells specifically blocked in G1 phase by
lovastatin, in S phase by thymidine and G2/M phases by
nocodazol. Arrested cells were treated with OH-TAM or ICI
1 mM for 24 h in the presence of cell cycle drugs and the effects on
ERa regulated gene expression were analyzed in each cell cycle
phase (Figure 4). We observed that OH-TAM and ICI both
altered gene expression during the different cell cycle phases.
Changes in transcription were not identical for these two
antiestrogens. For example, while both drugs slightly stimulated
ESR1 transcription in G2/M, ICI activated ESR1 and OH-TAM
repressed ESR1 expression in G1 arrested cells. The negative
feedback induced by reduction in ERa protein levels in the
presence of ICI thus stimulates ESR1 transcription in G1. The
inhibitory effect of both antiestrogens was most significant on PGR
in G1 arrested cells. Interestingly, while neither OH-TAM nor ICI
had an effect on CCND1 expression in G1 or G2/M, OH-TAM
reduced CCND1 expression by more than 40% in S phase. In
Regulation of ER Target Genes
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expression in G1 arrested cells but lead to a significant reduction of
its expression in S and G2/M phases.
Anti-estrogen action on cell proliferation is enhanced in
cells blocked in S-phase
We examined the consequence of antiestrogen addition during
each cell cycle phase on cell proliferation by a doubling time
experiment (Figure 5). The doubling time of untreated MCF-7
cells (NT) is usually 28 h (Figure 2A and 5A). OH-TAM (TAM),
ICI (ICI) (Figure 3) and lovastatin (Lova) (Figure 1) treatments
induced a significant G1 block, but a portion of the cell population
continued to proliferate (1.3 fold after 48 h) (Figure 5A).
Thymidine (Th) and nocodazol (Noco) stop cell proliferation
without any measurable impact on cell survival up to 48 h. Cells
appear to arrest in their respective cell cycle phase (S and G2/M
phases) respectively (Figure 1). No significant change in cell
proliferation is observed when MCF-7 cells blocked in G1 by
lovastatin (Figure 5B) or in G2/M (Figure 5D) by nocodazol were
treated with OH-TAM or ICI during 48 h. However, both
antiestrogens severely reduced the number of living cells when
applied in S phase: after 24 h treatment only 50% of cells
remained (Figure 5C).
We thus determined whether cell cycle drugs alone or in
combination with anti-estrogens induced apoptosis (Figure 6A).
MCF-7 cells were treated as above, whole cell extracts were
subjected to Western blotting using anti PARP-1 antibody.
Cleaved PARP was quantified by Image gauge software and
normalized by GAPDH expression (Figure 6B). 6 hours treatment
with staurosporin at 1 mM was used as a positive control of
apoptosis and quantification of cleaved PARP after this treatment
was set to 1 [22]. Only cells treated with OH-TAM or ICI in S-
Figure 1. ERa target gene expression is cell cycle regulated in MCF-7 cells. A) FACS analysis after propidium iodide staining on
asynchronous untreated cells (1), cells blocked in G1 by lovastatin treatment 20 mM for 32 h (2), in S phase by thymidine treatment 3 mM for 24 h (3)
or in G2/M by nocodazol 50 ng/ml for 24 h (4). B) Real-time PCR analysis of ESR1, PGR, CCND1 and H2AFZ gene expression in G1 (lovastatin), S
(thymidine) and G2/M (nocodazol) cell cycle phases. 2610
6 of MCF-7 cells were seeded in 10 cm dishes and after 24 h submitted to specific cell cycle
arrest drugs as in (A). Total RNA was extracted and reverse transcribed. The amount of analyzed genes cDNA was measured RT-qPCR divided by the
amount of RLP0 cDNA. (n=3) one representative experiment is shown. C) Real-time PCR analysis of ESR1, PGR, CCND1 and H2AFZ gene expression. For
lovastatin treatment cells were treated as in (B). For nocodazol/check-off treatment, 12610
6 cells were splited into two 140 cm dishes. After 24 h of
nocodazol treatment (25 ng/ml), G2/M arrested cells are harvested by check-off.and seeded in a clean dish. After 7 hours in complete medium total
RNA was extracted and reverse transcribed (n=2).
doi:10.1371/journal.pone.0011011.g001
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6 ERa-positive MCF-7 cells were
cultivated in red medium (R) for 24 h, then medium was removed and cells were cultivated in red or white medium A) FACS analysis of MCF-7 cells
after 4 days in red medium only (R), 3 days in red medium complemented with E2 10
28 M for 24 h, in white medium only for 4 days (W) or 3 days in
white medium complemented with E2 10
28 M for 24 h (W+E2). For growth curves, 1610
6 ERa-positive MCF-7 cells were cultivated in red medium (R)
for 24 h, then medium was removed and cells were cultivated in red or white medium. Cells were counted by trypan blue exclusion at different time
points. B) ESR1, PGR and CCND1 gene expression was analyzed by RT-qPCR.
doi:10.1371/journal.pone.0011011.g002
Figure 3. OH-TAM and ICI induced G1 cell cycle block and decreased ERa target gene expression. 2610
6 MCF-7 cells were cultivated in
red medium for 24 h. OH-TAM or ICI were added to the medium at a final concentration of 1 mM. After 24 h cell cycle was analyzed by FACS and
expression of ERa target genes by RT-qPCR.
doi:10.1371/journal.pone.0011011.g003
Regulation of ER Target Genes
PLoS ONE | www.plosone.org 4 June 2010 | Volume 5 | Issue 6 | e11011phase (thymidine arrested cells) accumulated cleaved PARP to
levels comparable to those detected in cells treated with
staurosporin. Under all other conditions, anti-estrogen treatment
alone or in G1 or G2/M arrested cells induced no or very little
accumulation of cleaved PARP. In addition, trypan blue staining
revealed that the percentage of trypan blue positive cells was .5
times higher in S-phase arrested cells treated with antiestrogens
(,20%) than in untreated or in thymidine arrested cells
(Figure 6C).
Synchronizing MCF-7 cells with hydroxy urea (HU) 1,5 mM or
aphidicolin (Ap) 1 mg/ml for 24 h prior to antiestrogen treatment
also blocked cells in S-phase without any measurable impact on
cell survival (Figure 6D). However, similarly to cells arrested by
thymidine, addition of OH-TAM and ICI to HU or Ap treated
Figure 4. Effect of OH-TAM and ICI on gene expression is cell cycle dependent. 2610
6 cells were cultivated in red medium for 24 h. Cells
were blocked in G1 by lovastatin 20 mM, 32 h (1), in S by thymidine 3 mM 24 h (2) and in G2/M by nocodazol 50 ng/ml, 24 h (3). Cell cycle arrested
cells were treated by Tamoxifen (OH-TAM 1 mM, 24 h) or ICI 182.780 (ICI 1 mM, 24 h). (n=2) one representative experiment is shown. Relative mRNA
expression in G1, S or G2/M phases of ERa target with or without anti-estrogen treatment was analyzed by RT-qPCR.
doi:10.1371/journal.pone.0011011.g004
Figure 5. Effect of OH-TAM and ICI on cell proliferation is enhanced in S-phase. 3610
5 MCF-7 cells were split in 60 cm dishes and
cultivated in red medium for 12 h. A) Cells were treated by lovastatin (20 mM, 32 h), thymidine (3 mM, 24 h) or nocodazol (50 ng/ml, 24 h) until T0.
Cell proliferation was monitored for untreated (NT) or for OH-TAM (1 mM) or ICI (1 mM) treated cells. Cells were counted by trypan blue exclusion in
triplicate at different time points. Number of cells at T0 was set to 1 and the doubling time was calculated. B-C-D). Cells were treated by lovastatin
20 mM for 32 h (B), by thymidine 3 mM, 24 h (C) or nocodazol 50 ng/ml, 24 h (D) until T0. Then, OH-TAM 1 mM or ICI 1 mM added to the medium and
cells were counted by trypan blue exclusion in triplicate at different time points.
doi:10.1371/journal.pone.0011011.g005
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5 MCF-7 cells were split in 60 cm
dishes and cultivated in red medium for 12 h. Cells were treated by lovastatin (20 mM, 32 h), thymidine (3 mM, 24 h) or nocodazol (50 ng/ml, 24 h)
until T0. Accumulation of cleaved PARP (black arrow) was monitored by western blotting for untreated (NT) or for OH-TAM (1 mM) or ICI (1 mM)
treated cells. B) Quantification analysis was performed using the ImageGauge 4.0 software. * increase .50% of cleaved PARP. C) 3610
6 cells were
seeded in 10 cm dishes. After 12 h, cells were treated or not (NT) with 3 mM thymidine for 24 h. Cells were treated with thymidine (Th) or Tamoxifen
1 mM (Th + TAM), ICI 100 nM or 1 mM (Th + ICI) for 24 h. After trypsinisation, cells were counted by trypan blue staining. Total cell number was set to
100% (n=2). D) 3610
6 cells were splited in 10 cm dishes. At T0 cells were treated with hydroxyl urea 1,5 mM or aphidicolin 1 mg/ml for 24 h. Then,
cells were treated or not with Tamoxifen or ICI 1 mM for another 24 h. Cells were counted by trypan blue exclusion. Number of cells at T0 was set to 1
Regulation of ER Target Genes
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(Figure 6D). The amount of cleaved PARP1 was about 50%
greater in antiestrogen treated, S-phase arrested cells than in
untreated cells arrested by HU or Ap (Figure 6E). Hence, the
impact of antiestrogens on cell survival is potentiated in S-phase
independently of the treatment used to synchronize cells.
Furthermore, this reduction of cell survival correlated with a
significant decrease in cyclin D1 transcription in cells treated with
antiestrogens in S-phase (Figure 4A) and a clear reduction of the
growth rate of these cells at 24 and 48 h (Figure 5). Taken
together, these data clearly demonstrate that the impact of anti-
estrogen treatment depends on the cell cycle phase.
Discussion
We show that in MCF-7 cells the estrogen receptor and
downstream target genes are cell cycle regulated with expression
levels varying as much as three-fold between phases of the cell
cycle. Thus, cell cycle effects have to be taken into account when
interpreting data obtained from assays involving drugs that affect
cell cycle progression. Indeed, under commonly employed culture
conditions used to assess the effect of hormones on gene expression
(steroid free or ‘white medium), MCF-7 cells arrest in G1.
Importantly, several ERa target genes are overexpressed in G1
relative to G2/M. In particular, the apparent increase in ESR1
gene expression may partially be a cell cycle effect. Interaction
between unbound ERa and p21
WAF1 has previously been
proposed to have an antiproliferative effect [23]. This effect could
be exacerbated by increased ERa levels in G1. Since cells return to
cycle normally only after 24 h, such protein-protein interactions
may modulate gene expression specifically in ‘‘white’’ medium.
We further demonstrate that antiestrogen effectiveness is largely
influenced by the cell cycle. One of the most commonly used
antiestrogens is Tamoxifen [24], also called SERM, for selective
estrogen receptor modulator. Pure antagonists such as ICI
164.384 or ICI 182.780 have been developed to avoid undesirable
side effects due to stimulating effects of SERMs in other tissues.
We noticed significant variability in gene expression between OH-
TAM and ICI treated cells in different cell cycle phases. For
example, in G1, ESR1 transcription was inhibited by OH-TAM
but activated by ICI. Yet, in G2/M, OH-TAM and ICI both
activated ESR1 expression. It is likely that these differences stem
from the different mode of action of these antiestrogens. OH-
TAM bound ERa recognizes ERE sequences of target genes, but
recruits several co-repressors in mammary tumor cells due to a
conformational change induced by OH-TAM [25,26]. ICI bound
ERa is in a non-functional conformation and hydrolyzed by the
proteasome – in any cell cycle phase.
We demonstrate for the first time that the effect of OH-TAM
and ICI on target gene expression varies depending on cell cycle
phase. One would expect OH-TAM and ICI to repress
transcription, yet CCND1 transcription is not decreased when
using OH-TAM or ICI in G1 cells. The repressive effect is only
seen in S-phase. Inversely, these AEs do not affect ESR1
transcription in S phase and differentially regulate ESR1 in G1
or G2 phase.
Tamoxifen and ICI arrest cells in G0/G1 ([15,27]; Figure 5).
This anti-proliferative activity is associated with an inhibition of
Cdk activity, a decrease in pRB phosphorylation, as well as a
decrease in expression of several ERa target genes including
Cyclin D1, c-Myc or Cyclin E [28,29] but an increase in p21 and
p27 expression [24,30]. Cyclin D1, a key regulator of the G1/S
transition and PI3K/AKT and MAPK signaling pathways, acts as
mitogenic sensor in G1 [31,32,33]. CCND1 is one of the most
commonly overexpressed genes in breast cancer (up to 50% of
breast cancers) [33,34]. Its overexpression in mice leads to
development of mammary carcinoma, while down-regulation
induces resistance to cancer development [35,36]. Its regulation is
complex and upon E2 stimulation different transcriptional
complexes can modulate CCND1 transcription by direct ERa
mediated genomic function but also as an indirect regulation of the
activity of co-factors trough E2-induced non genomic effects [37].
Interestingly, antiestrogens repress transcription of all ERa
target genes tested in S phase. This observation corroborates the
more rapid and strong impact of antiestrogen treatments on cell
proliferation in S-phase compared to similar treatments in G1 or
in G2/M. Only in S-phase, MCF-7 cells induced massive
apoptosis in the presence of 1 mM anti-estrogens. While it has
been reported that OH-TAM can induce cell death at .5 mMi n
MCF-7 cells, little or no apoptosis was observed at 1 mM [38]. In
vivo the percentage of apoptotic death within tumors was also low
(about 5%) [39,40]. Nevertheless, different signalling pathways
have been implicated in OH-TAM or ICI-induced apoptosis (such
as protein kinase C, c-MYC, p53 or MAP kinase) the exact
mechanism is still unknown [41,42]. Reduction in cyclin D1
transcription cannot explain this effect. It will be interesting to
search for S-phase specific genes that are directly or indirectly
ERa regulated and sensitive to antiestrogen treatments. Although
not a direct target of ERa, the PCNA gene is a potential candidate
[43]. Indeed, PCNA is upregulated in MCF-7 cells in the presence
of E2 [7] and thus its regulation may be sensitive to antiestrogens.
Possibly, replication may be defective due to reduced PCNA levels
upon anti-estrogen treatment of cells in S-phase. Non functional
PCNA has also been linked to apoptotic effects [44,45]. The effect
of antiestrogens in S-phase is most likely indirect by affecting
numerous signalling pathways, including the AKT phosphoryla-
tion activity which activates Chk1 and other factors necessary for
replication origin firing. Any perturbation of the frequency of
replication origin firing will induce replicative stress which in turn
activates p53 and downstream events, including apoptosis [46].
From a clinical point of view, the induction of apoptosis is an
important component of breast cancer regression. The enhanced
effects of antiestrogens specifically in S-phase, suggest that
associating antiestrogens and cell cycle drugs represent a
therapeutically attractive avenue.
Materials and Methods
Reagents
Estradiol, Thymidine, Nocodazol, Lovastatin (Mevinolin),
Tamoxifen (OH-TAM), Hydroxy urea, Aphidicolin and Staur-
osporin were purchased from Sigma-Aldrich (Saint-Quentin
Fallavier, France). ICI 182.780 (ICI) was purchased from
TOCRIS (MO, USA).
Cell lines and tissue culture
MCF-7 cells purchased from ATCC (passage No. 146, used up
to 10 passages), were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) F-12 with Glutamax containing 50 mg/ml
gentamicin, 1 mM sodium pyruvate and 10% heat-inactivated
and the doubling time was calculated. E) Cells were treated as in (D). Accumulation of cleaved PARP (black arrow) was monitored by western blotting.
Quantification analysis was performed using the ImageGauge 4.0 software. * increase .50% of cleaved PARP.
doi:10.1371/journal.pone.0011011.g006
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because of the presence of phenol red. For steroid free medium or
white medium (W), cells were grown for 3 days in media without
phenol red, 50 mg/ml gentamicin, 1 mM sodium pyruvate and
10% of serum stripped of endogenous steroids. Cells were treated
or not with 10
28 M E2, 1 mM OH-TAM, 1 mM ICI, 20 mM
Lovastatin, 3 mM Thymidine, 50 ng/ml Nocodazol, 1,5 mM
Hydroxy urea, 1 mg/ml Aphidicolin for the indicated times. For
‘check-off’, MCF-7 cells were treated 24 h with 25 ng/ml of
nocodazol. After mechanical detachment (check-off) cells were
washed three times in PBS, one time with complete medium and
seeded in a new dish.
RNA extraction, reverse transcription and Quantitative
PCR analysis
Total RNA was extracted using an RNeasy mini kit (Qiagen)
and eluted with 35 ml of RNAase-free water. First strand cDNA
was generated using 2 mg of total RNA in a reaction containing
random oligonucleotides as primers with the ThermoScript RT-
PCR system (Invitrogen). Real-time PCR was performed on
MastercyclerH ep realplex
4 (Eppendorf) using the platinium SYBR
Green qPCR SuperMix (Invitrogen) according to the manufac-
turer’s instructions. Amplification conditions: 1 min at 50uC,
3 min at 95uC followed by 40 cycles (20 s at 95uC, 20 s at 60uC,
20 s at 72uC). The following primer pairs were used to amplify
cDNAs after reverse transcription experiment ESR1: 59- TGGA-
GATCTTCGACATGCTG - 39 and 59- TCCAGAGACTT-
CAGGGTGCT-39, PGR: 59-CTTAATCAACTAGGCGAGAG-
39 and 59-AAGCTCATCCAAGAATACTG-39 H2AFZ: 59-
CCTTTTCTCTGCCTTGCTTG-39 and 59-CGGTGAGG-
TACTCCAGGATG-39, CCND1: 59- GCGTCCATGCGGAA-
GATC-39 and 59-ATGGCCAGCGGGAAGAC-39. Expression of
PRPLP0 was used as control. PRPLP0: 59-TGGCAGCATCTA-
CAACCCTGAA-39 and 59- ACACTGGCAACATTGCG-
GACA- 39. Experiments were repeated two times.
Western blotting
Samples were separated by SDS–polyacrylamide gel electro-
phoresis. Anti-PARP-1 antibody was purchased by Alexis
Biochemicals (ALX 210-895) and was used at 1/2000 dilution,
anti-GAPDH from Millipore (MAB 374) was used at 1/1000
dilution. Quantification analysis was performed using the
ImageGauge 4.0 software.
Flow cytometry (FACS)
Cells were harvested directly from culture plates. After
centrifugation at 1400rpm, 4uC, 5 mn, the pellet was washed
with PBS/BSA 1% and resuspended in 500 ml PBS. Cells were
fixed by adding 1.5 ml 100% cold ethanol and left at least 2 h at
220uC. Then, cells were washed with 4 ml PBS/BSA 1%. After
centrifugation (4 min, 1400 rpm 4uC, 5 mn) the pellet was
resuspended in FACS buffer: 500 ml PBS, RNAse A 1 mg/ml,
Propidium Iodide 10 mg/ml and incubated 30 min, 37uC in the
dark. Cell cycle profile was analysed with a Facscalibur apparatus
(BD Biosciences).
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